SPARC Sun Pharma Advanced Research Company Q3 FY26 results (Oct–Dec 2025) and concall
SPARC provided a strategic update focusing on pipeline prioritization, cost optimization, and progress in key clinical programs. The company reported significant fixed cost savings and a reduction in operational spend. Key programs SCD-153 and SBO-154 are advancing through clinical trials with upcoming readouts. While a favorable PRV ruling offers potential upside, challenges remain for PDP-716 and vodobatinib, and the portfolio is acknowledged as early-stage.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q3 FY26: revenue down 46.7%, net profit up 0.0% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 13 | 15 | 27 | 10 | 8 −38% | 8 −47% |
| EBITDA | -103 | -74 | -53 | -52 | -66 +36% | -57 +23% |
| Net profit | -107 | -80 | -60 | -52 | -76 +29% | -80 +0% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
